Dong-A Vows Legal Steps As Korea Imposes Heavy Penalties Over Rebates
Executive Summary
Korea temporarily suspends reimbursement of drugs involved in Dong-A ST’s alleged illegal rebate payments to doctors, raising concerns from the industry whether the new measures are appropriate. The company concedes it violated the Pharmaceutical Affairs Act but vows to seek legal redress as it claims there are substantial issues with the punitive measures.
You may also be interested in...
Korea Revises Rules To Curb Rebate Activities, Improve Ethics
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.